Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes

Novo Nordisk A/S19 enrolled

Overview

This trial is conducted in Europe. The aim of this trial is to examine the effect of NNC 90-1170 on the hypoglycaemic counterregulation in subjects with type 2 diabetes.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Diabetes Diabetes Mellitus, Type 2

Interventions

liraglutideDRUG

Single dose of 7.5 mcg/kg, injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement

placeboDRUG

Single dose injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement

Eligibility

Sex: ALLMin age: 30 YearsMax age: 75 Years

Medical Language ↔ Plain English

age: minimum 30, maximum 75 years

Locations (1)

Novo Nordisk Investigational Site

Bad Lauterberg im Harz, Germany

Outcomes

Primary Outcomes

Area under the Curve (AUC) glucagon

Secondary Outcomes

Insulin secretion

Glucose

Cortisol

Growth hormone

Adrenaline

Noradrenaline

Adverse events

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.